What is Vaxart Inc?
, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 119.16M, and a P/E ratio of 2.9x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.